Stereotaxis, Inc. (NYSE: STXS)

Stereotaxis, Inc. designs, manufactures and markets robotic systems, instruments and information systems for the interventional laboratory. The company's core technology, Robotic Magnetic Navigation, employs computer controlled magnetic fields to steer the tips of catheters and guidewires, enabling precise, remote controlled procedures. This technology is primarily applied in electrophysiology for cardiac ablation procedures but is also being developed for coronary, neuro and peripheral vascular interventions. Stereotaxis supports its systems with a suite of disposable devices, software platforms such as Synchrony and SynX, and ancillary offerings like integrated fluoroscopy systems through partnerships with equipment manufacturers.

Revenue is derived from the sale of its robotic magnetic navigation systems, including the Genesis RMN and GenesisX RMN platforms. The company also generates income from disposable interventional devices such as the MAGiC ablation catheter, Map iT diagnostic catheters and related accessories that are used with its systems. Additional revenue streams include software and information solutions like the Synchrony and SynX platforms, which provide lab workflow integration, remote connectivity and data management. Stereotaxis earns service revenue from maintenance contracts, service type warranties and post warranty support for its equipment and software. The company reports a system backlog of $9.1 million as of December 31, 2025, reflecting pending purchase orders for its systems that are expected to convert to revenue over the following year.

The company operates through the following segments.

• Single operating segment: This segment covers the design, manufacture and sale of robotic magnetic navigation systems, disposable devices, software solutions and related service offerings for the interventional laboratory, including system integration with third party fluoroscopy equipment.

Stereotaxis holds a distinctive position as the sole provider of commercially cleared remote, digital, direct control catheter technology for radiofrequency ablation procedures. The company competes against conventional manual catheter techniques, emerging robotic navigation firms and established imaging and equipment manufacturers that offer alternative electrophysiology solutions. Its competitive advantages arise from the precision and stability of magnetic navigation, the reduction of physician radiation exposure and the ability to integrate procedural data into a unified lab interface. Stereotaxis benefits from a substantial body of clinical evidence, with over 150,000 procedures performed and more than 500 peer reviewed publications supporting the safety and efficacy of its technology. The firm continues to invest in research and development to expand its platform into coronary, neuro and peripheral vascular applications, aiming to broaden its addressable market.

The company serves hospitals, electrophysiology labs and interventional cardiology centers that perform catheter based procedures. Its customer base includes academic medical centers, community hospitals and specialty clinics seeking to adopt robotic navigation for arrhythmia treatment and other vascular interventions. No single customer accounted for more than 10% of total revenue in the most recent fiscal years, and no individual country outside the United States contributed more than 10% of revenue. Stereotaxis distributes its products globally through a direct sales force, distributors and agents, supporting installations in North America, Europe and select Asian markets.